Table 4 Subgroup analysis: baseline demographics of patients with idiopathic pulmonary fibrosis before and after propensity score matching – intensive care unit respiratory hospitalizations without mechanical ventilation
| Â | Before propensity score matching | After propensity score matching | ||||
|---|---|---|---|---|---|---|
No Rx (N = 1288) | Pirfenidone/Nintedanib (N = 180) | Std. Diff | No Rx (N = 180) | Pirfenidone/Nintedanib (N = 180) | Std. Diff | |
Age group | ||||||
45–64 | 168 (13.0%) | 24 (13.3%) | 0.010 | 30 (16.7%) | 24 (13.3%) | − 0.093 |
65–74 | 341 (26.5%) | 65 (36.1%) | 0.208 | 65 (36.1%) | 65 (36.1%) | 0.000 |
75 +  | 779 (60.5%) | 91 (50.6%) | − 0.201 | 85 (47.2%) | 91 (50.6%) | 0.067 |
Gender | ||||||
Female | 587 (45.6%) | 52 (28.9%) | − 0.352 | 55 (30.6%) | 52 (28.9%) | − 0.036 |
Male | 699 (54.4%) | 128 (71.1%) | 0.352 | 125 (69.4%) | 128 (71.1%) | 0.036 |
Race | ||||||
White | 834 (64.8%) | 121 (67.2%) | 0.050 | 118 (65.6%) | 121 (67.2%) | 0.035 |
Black | 93 (7.2%) | 5 (2.8%) | − 0.205 | 7 (3.9%) | 5 (2.8%) | − 0.062 |
Hispanic | 131 (10.2%) | 16 (8.9%) | − 0.044 | 17 (9.4%) | 16 (8.9%) | − 0.019 |
Other | 230 (17.9%) | 38 (21.1%) | 0.086 | 38 (21.1%) | 38 (21.1%) | 0.000 |
Census region | ||||||
Midwest | 386 (30.0%) | 44 (24.4%) | − 0.125 | 40 (22.2%) | 44 (24.4%) | 0.053 |
Northeast | 173 (13.4%) | 22 (12.2%) | − 0.037 | 27 (15.0%) | 22 (12.2%) | − 0.081 |
South | 606 (47.0%) | 93 (51.7%) | 0.094 | 90 (50.0%) | 93 (51.7%) | 0.033 |
West | 123 (9.5%) | 21 (11.7%) | 0.068 | 23 (12.8%) | 21 (11.7%) | − 0.034 |
Baseline comorbidities | ||||||
Cardiac Arrhythmia | 542 (42.1%) | 78 (43.3%) | 0.027 | 80 (44.4%) | 78 (43.3%) | − 0.022 |
Congestive Heart Failure | 508 (39.4%) | 59 (32.8%) | − 0.137 | 63 (35.0%) | 59 (32.8%) | − 0.047 |
Other Chronic Pulmonary Conditions | 964 (74.8%) | 115 (63.9%) | − 0.240 | 118 (65.6%) | 115 (63.9%) | − 0.035 |
Depression | 242 (18.8%) | 29 (16.1%) | − 0.071 | 27 (15.0%) | 29 (16.1%) | 0.031 |
Diabetes | 509 (39.5%) | 68 (37.8%) | − 0.034 | 69 (38.3%) | 68 (37.8%) | − 0.011 |
Hypertension | 996 (77.3%) | 129 (71.7%) | − 0.129 | 132 (73.3%) | 129 (71.7%) | − 0.037 |
Pulmonary Circulation Disorder | 337 (26.2%) | 59 (32.8%) | 0.144 | 62 (34.4%) | 59 (32.8%) | − 0.035 |
Renal Failure | 302 (23.4%) | 39 (21.7%) | − 0.042 | 37 (20.6%) | 39 (21.7%) | 0.027 |
Solid Tumor without Metastasis | 183 (14.2%) | 30 (16.7%) | 0.067 | 27 (15.0%) | 30 (16.7%) | 0.046 |
Valvular Disease | 344 (26.7%) | 39 (21.7%) | − 0.115 | 40 (22.2%) | 39 (21.7%) | − 0.013 |
Elixhauser comorbidity index | ||||||
Mean (SD) | 5.8 (3.2) | 5.3 (2.8) | − 0.166 | 5.4 (3.0) | 5.3 (2.8) | − 0.050 |
Median | 5.0 | 5.0 | −  | 5.0 | 5.0 | −  |
Q1, Q3 | 3.0, 8.0 | 3.0, 7.0 | −  | 3.0, 7.0 | 3.0, 7.0 | −  |
N hospitalizations in baseline | ||||||
0 | 749 (58.2%) | 120 (66.7%) | 0.176 | 115 (63.9%) | 120 (66.7%) | 0.058 |
1 | 324 (25.2%) | 43 (23.9%) | − 0.030 | 43 (23.9%) | 43 (23.9%) | 0.000 |
2 +  | 215 (16.7%) | 17 (9.4%) | − 0.215 | 22 (12.2%) | 17 (9.4%) | − 0.089 |
Year of hospitalization | ||||||
2015 | 272 (21.1%) | 18 (10.0%) | − 0.311 | 17 (9.4%) | 18 (10.0%) | 0.019 |
2016 | 294 (22.8%) | 39 (21.7%) | − 0.025 | 36 (20.0%) | 39 (21.7%) | 0.041 |
2017 | 332 (25.8%) | 57 (31.7%) | 0.130 | 61 (33.9%) | 57 (31.7%) | − 0.047 |
2018 | 390 (30.3%) | 66 (36.7%) | 0.135 | 66 (36.7%) | 66 (36.7%) | 0.000 |
Reason for admission | ||||||
Diseases of respiratory system | 790 (61.3%) | 89 (49.4%) | − 0.240 | 85 (47.2%) | 89 (49.4%) | 0.044 |
Diseases affecting the interstitium | 379 (29.4%) | 88 (48.9%) | 0.406 | 91 (50.6%) | 88 (48.9%) | − 0.033 |
All other reasons | 119 (9.2%) | 3 (1.7%) | − 0.399 | 4 (2.2%) | 3 (1.7%) | − 0.040 |
Pulmonologist visit | 728 (56.5%) | 145 (80.6%) | 0.535 | 150 (83.3%) | 145 (80.6%) | − 0.072 |
Smoker | 652 (50.6%) | 89 (49.4%) | − 0.024 | 92 (51.1%) | 89 (49.4%) | − 0.033 |
Steroid use | 725 (56.3%) | 114 (63.3%) | 0.144 | 114 (63.3%) | 114 (63.3%) | − 0.000 |
Oxygen use | 765 (59.4%) | 145 (80.6%) | 0.431 | 143 (79.4%) | 145 (80.6%) | − 0.041 |